Our Mission
We discovered the physics layer of biology.
InfiniGraph was founded on a discovery that changes the economics of drug development — every protein carries a physical signature that governs how it responds to drugs, and no existing tool could calculate it. We built HARMONY to change that.
Why We Exist
Drug discovery has a physics problem.
The pharmaceutical industry spends $2.6 billion and 12 years bringing the average drug to market — and 90% of candidates still fail in clinical trials. The root cause is not bad chemistry. It is an inability to predict, before spending hundreds of millions, how a protein will actually behave when a drug tries to bind to it. InfiniGraph built the equations to answer that question.
Physics Before Statistics
We do not train models on historical drug data and call it intelligence. Every result HARMONY produces is derived from the laws of physics — reproducible, traceable, and defensible in front of any scientific or regulatory audience.
Speed That Matters
5 seconds per protein. Under $50 per run. In drug discovery, every month of delay is a month patients wait. HARMONY compresses the earliest and most critical stage of drug development from years to hours.
Safety Is Architecture
Unsafe molecules cannot be produced by HARMONY. The safety filter is not a post-hoc check — it runs inside every generation loop, blocking harmful compounds before they are ever proposed.
A Platform for Partners
HARMONY is not a bet on one drug. It is infrastructure that can run across any target, any disease, any indication. We are actively seeking pharma and biotech partners who see the same opportunity we do.
Leadership
Physics, medicine, and execution.
InfiniGraph is led by a founding team that has built category-defining companies, published in Nature, and invented the physics that makes HARMONY possible. Meet the full team →
Chase K. McMichael
Founder · CEO · CSO
Physicist. Discoverer of backbone dihedral perturbation analysis. Architect of HARMONY. Inventor of record on all method patents and 9 Composition of Matter families. 7 provisional patents, 210+ claims filed.
Lincoln D. Nadauld, MD, PhD
Chief Medical Officer
Practicing precision oncologist at Intermountain Health. First and senior author in Nature Genetics and Nature. Leads clinical development strategy and ClinVar-based target selection.
Michael Wiley, JD
General Counsel
Co-founder of Guardant Health (NASDAQ: GH, $3B+ market cap). Deep expertise in life science IP strategy, licensing, and commercialization. Oversees InfiniGraph's IP fortress and pharma partnership structure.
The biggest fortunes in biotech were made by people who saw the platform before everyone else did. HARMONY is that platform.
InfiniGraph — Company Vision